Alzamend Neuro Inc (NASDAQ:ALZN) has posted positive topline data from its Phase 1 trial for AL001 as an oral treatment for dementia-related to Alzheimer's disease.
- The trial was designed to determine the pharmacokinetics, safety, and tolerability of AL001 and target doses for a planned Phase 2 study in Alzheimer's patients.
- Related Link: See Why Alzamend Neuro Stock Is Rallying On Thursday.
- The participants received a single dose of AL001 containing lithium equivalent to 150 mg lithium carbonate.
- Dose-adjusted relative bioavailability analyses of the rate and extent of lithium absorption indicate that AL001 is bioequivalent to the marketed 300 mg lithium carbonate product.
- The shapes of the lithium plasma concentration versus time curves are similar.
- AL001 salicylate plasma concentrations were well-tolerated and consistently within safe limits.
- AL001 is a patented ionic cocrystal technology delivering lithium via a therapeutic crystal-engineered combination of lithium, L-proline, and salicylate.
- Price Action: ALZN shares are up 14.20% at $2.89 during the market session on the last check Friday.
